Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer
European Journal of Cancer(2022)
Abstract
Image 1
MoreTranslated text
Key words
CDK4/6 inhibitor,Neoadjuvant,Luminal breast cancer,Chemotherapy,Survival
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined